Neurotrope 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 08, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1,513,856
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		49,727,596

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 8,958,192	$ 11,230,637
Prepaid expenses	97,877	1,489,851
Subscription receivable	0	2,761
TOTAL CURRENT ASSETS	9,056,069	12,723,249
Fixed Assets, net of accumulated depreciation	58,670	59,175
TOTAL ASSETS	9,114,739	12,782,424
CURRENT LIABILITIES
Accounts payable	699,511	449,875
Accrued expenses	178,460	141,525
Note payable	0	10,511
Accrued expenses - related party	351,344	389,058
TOTAL CURRENT LIABILITIES	1,229,315	990,969
Commitments and contingencies
SHAREHOLDERS' DEFICIT
Common stock - 400,000,000 shares authorized, $.0001 par value; 49,627,596 issued and outstanding at June 30, 2016; 49,170,232 shares issued and outstanding at December 31, 2015	4,962	4,917
Additional paid-in capital	28,304,453	27,695,888
Accumulated deficit	(32,045,215)	(27,724,224)
TOTAL SHAREHOLDERS' DEFICIT	(3,735,800)	(23,419)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	9,114,739	12,782,424
Series B Convertible Redeemable Preferred Stock [Member]
CONVERTIBLE REDEEMABLE PREFERRED STOCK
Convertible redeemable preferred stock, Series B, $.0001 par value, 333,333 shares authorized; 258,049.4 issued and outstanding at June 30, 2016 and 262,349.4 shares issued and outstanding at December 31, 2015 Liquidation preference of $15,482,963 at June 30, 2016 and $15,740,963 at December 31, 2015. plus dividends accruable at 13.3% per annum of $1,304,576 as of June 30, 2016 and $279,824 as of December 31, 2015.	$ 11,621,224	$ 11,814,874

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	49,627,596	49,170,232
Common stock, shares outstanding	49,627,596	49,170,232
Series B Convertible Redeemable Preferred Stock [Member]
Convertible redeemable preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible redeemable preferred stock, shares authorized	333,333	333,333
Convertible redeemable preferred stock, shares issued	258,049.4	262,349.4
Convertible redeemable preferred stock, shares outstanding	258,049.4	262,349.4
Convertible redeemable preferred stock, Liquidation Preference, Value (in dollars)	$ 15,482,963	$ 15,740,963
Dividends Payable Percentage (in percentage)	13.30%	13.30%
Dividends Payable (in dollars)	$ 1,304,576	$ 279,824

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
OPERATING EXPENSES:
Research and development - related party	$ 264,558	$ 615,881	$ 514,558	$ 1,215,881
Research and development	925,942	586,821	1,818,679	1,079,478
General and administrative - related party	27,000	27,000	54,000	54,000
General and administrative	767,649	1,237,982	1,523,001	2,424,340
Stock-based compensation - related party	43,818	43,818	87,635	87,154
Stock-based compensation	165,823	139,375	327,052	157,861
TOTAL OPERATING EXPENSES	2,194,790	2,650,877	4,324,925	5,018,714
OTHER INCOME:
Interest income	1,856	921	3,934	2,489
Net loss before income taxes	(2,192,934)	(2,649,956)	(4,320,991)	(5,016,225)
Provision for income taxes	0	0	0	0
Net loss	(2,192,934)	(2,649,956)	(4,320,991)	(5,016,225)
Preferred Stock dividends	(504,712)	(339,146)	(1,024,752)	(674,565)
Net loss attributable to common shareholders	$ (2,697,646)	$ (2,989,102)	$ (5,345,743)	$ (5,690,790)
PER SHARE DATA:
Basic and diluted loss per common share	$ (0.05)	$ (0.11)	$ (0.11)	$ (0.22)
Basic and diluted weighted average common shares outstanding	49,373,000	27,623,000	49,237,000	25,829,000

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' Deficit - 6 months ended Jun. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (23,419)	$ 4,917	$ 27,695,888	$ (27,724,224)
Balance (in shares) at Dec. 31, 2015		49,170,232
Conversion of Series B preferred stock to common stock	193,650	$ 43	193,607	0
Conversion of Series B preferred stock to common stock (in shares)		430,000
Stock based compensation	414,687	$ 0	414,687	0
Exercise of common stock warrants	274	$ 2	271	0
Exercise of common stock warrants (in shares)		27,364
Net loss	(4,320,991)	$ 0	0	(4,320,991)
Balance at Jun. 30, 2016	$ (3,735,800)	$ 4,962	$ 28,304,453	$ (32,045,215)
Balance (in shares) at Jun. 30, 2016		49,627,596

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,320,991)	$ (5,016,225)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	414,687	245,015
Depreciation expense	3,451	3,049
Change in assets and liabilities
Decrease in prepaid expenses	1,391,974	22,018
Decrease in subscription receivable	2,761	0
(Decrease) in accrued expenses - related party	(37,714)	0
Increase in accounts payable	249,636	73,683
(Decrease) increase in accrued expenses	36,935	35,529
Total adjustments	2,061,730	379,294
Net Cash Used in Operating Activities	(2,259,261)	(4,636,931)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(2,947)	(11,827)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable	0	28,904
Repayments on note payable	(10,511)	(2,628)
Proceeds from exercise of common stock warrants	274	2,363
Net Cash (Used in) Provided by Financing Activities	(10,237)	28,639
NET DECREASE IN CASH	(2,272,445)	(4,620,119)
CASH AT BEGINNING OF PERIOD	11,230,637	8,010,357
CASH AT END OF PERIOD	$ 8,958,192	$ 3,390,238
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Conversion of convertible redeemable preferred stock to common stock	193,650	3,787,537

Organization and Nature of Plan

Organization and Nature of Planned Business:	6 Months Ended
	Jun. 30, 2016
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to certain technology were licensed by BRNI to the Company on February 28, 2013 (see Note 6 below). On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $ 0.0001 The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date. As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.” Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed consolidated financial statements included in this document have been prepared on the same basis as the annual consolidated financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with GAAP and SEC regulations for interim financial statements. The results for the six months ended June 30, 2016 are not necessarily indicative of the results that we will have for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K.

Going Concern_

Going Concern:	6 Months Ended
	Jun. 30, 2016
Going Concern [Abstract]
Going Concern [Text Block]	Note 2 – Going Concern: The unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, we have generated no revenues to date, have incurred substantial losses and have substantial contractual commitments pursuant to various agreements to which we are a party. Our ability to continue existence is dependent upon our continuing efforts to obtain additional financing to carry out our business plan. We intend to fund our operations through equity and/or debt financing arrangements and any revenues generated in the future. Any equity financing, if available, would most likely be significantly dilutive to our current stockholders. However, there can be no assurance that these arrangements, if any, will be sufficient to fund our ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all. These conditions raise substantial doubt as to our ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies:	6 Months Ended
	Jun. 30, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Significant Accounting Policies [Text Block]	Note 3 – Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain reclassifications have been made to the 2015 financial statements to conform to the consolidated 2016 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported. The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At June 30, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation. June 30, December 31, Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (11,046) (7,595) Property and equipment, net $ 58,670 $ 59,175 Depreciation expense for the six months ended June 30, 2016 and 2015 was $ 3,451 3,049 All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from BRNI that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at June 30, 2016 and December 31, 2015. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through June 30, 2016. The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to put most leases on their balance sheets by recognizing a lessee’s rights and obligations, while expenses will continue to be recognized in a similar manner to today’s legacy lease accounting guidance. This ASU could also significantly affect the financial ratios used for external reporting and other purposes, such as debt covenant compliance. This ASU will be effective for January 1, 2019, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation (Topic 718), which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements.

Contractual Commitments_

Contractual Commitments:	6 Months Ended
	Jun. 30, 2016
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 4 – Contractual Commitments The Company has entered into employment agreements with each of the executive officers of the Company. The agreements for these officers have remaining terms as of June 30, 2016 extending through 2017, as adjusted for recent management changes outlined in Note 11 - “Subsequent Events, providing for aggregate base salaries of approximately $ 380,000 350,000 On September 4, 2014, the Company entered into a long-term lease for 4,000 88,000 136,100

Collaborative Agreements_

Collaborative Agreements:	6 Months Ended
	Jun. 30, 2016
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 5 – Collaborative Agreements On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. During the six months ended June 30, 2016, the Company paid Stanford the annual maintenance fee of $ 10,000 On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company had agreed to pay fees to the CRO totaling $ 715,159 657,238 150,000 837,112 0 377,225 On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (“PKCe”), which includes Niemann-Pick Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Product(s)”) in the Mount Sinai Field of Use. During the six months ended June 30, 2016, the Company paid Mount Sinai $ 29,400 75 On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Services Agreement”) with WCT, effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2b clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD (the “Study”). Pursuant to the terms of the Services Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) Study subjects. The first Study site was initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, was approximately $ 11.6 200,000 On July 27, 2016, the Company received approval of the institutional review board (“IRB”) for our amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration relating to the Phase 2b clinical trial of our lead drug candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease, which amended protocol eliminates the second study period following the first 12 weeks of treatment (See Note 11 – “Subsequent Events”.) As a result, the Company believes that the total trial cost will be reduced. On November 11, 2015, Neurotrope BioScience paid WCT $ 1,875,861 928,000 268,000 680,000 9.5 533,000 Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its BRNI License Agreement (see Note 6 below).

Related Party Transactions and

Related Party Transactions and Licensing / Research Agreements:	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6 – Related Party Transactions and Licensing / Research Agreements One director of the Company, James Gottlieb, was also a director of BRNI as of June 30, 2016. William Singer was the president of BRNI until April 26, 2016. BRNI is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 18.2 Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement (the “TLSA”) with BRNI, a related party, and NRV II, LLC (“NRV II”), another affiliate of BRNI, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “BRNI License Agreement”). The BRNI License Agreement amended and restated the TLSA, as amended. Under the terms of the BRNI License Agreement, BRNI provides research services and has granted Neurotrope BioScience the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under BRNI’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by BRNI or licensed to NRV II by BRNI as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic and diagnostic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the TLSA specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the BRNI License. The BRNI License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After the initial Series A Stock financing, the BRNI License Agreement required Neurotrope BioScience to enter into scope of work agreements with BRNI as the preferred service provider for any research and development services or other related scientific assistance and support services. In addition, the BRNI License Agreement requires the Company to pay BRNI a “Fixed Research Fee” of $ 1 25,000,000 2 5 5 On November 12, 2015, Neurotrope BioScience, BRNI, and NRV II entered into an amendment (the “Amendment”) to the TLSA pursuant to which BRNI granted rights in certain technology to Neurotrope BioScience. Under the Amendment, the “Advances on Future Royalties” section of the TLSA was amended and restated to (i) eliminate the requirement that Neurotrope BioScience pay BRNI prepaid royalties equal to five percent ( 5 2.5 June 30, 2016 348,011 Pursuant to the BRNI License Agreement, on February 4, 2015, Neurotrope BioScience and BRNI entered into a new Statement of Work and Account Satisfaction Agreement (the “February 2015 SOW”). The February 2015 SOW was effective as of October 1, 2014 and ended on September 30, 2015. In consideration for the February 2015 SOW, BRNI agreed to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of BRNI’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of BRNI’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of BRNI’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with BRNI’s Investigative New Drug Application (IND) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKCε platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKCε activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for purpose of developing a commercially usable PKCε activator. Under the BRNI License Agreement, Neurotrope BioScience received a license to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of Alzheimer’s disease in humans (the “AD Diagnostic Test”). Further, under the February 2015 SOW, Neurotrope BioScience’s rights to the technology associated with the AD Diagnostic Test automatically reverted to BRNI based on certain contractual conditions on July 10, 2015. The remaining terms and conditions of the BRNI License Agreement, including the license of technology associated with Neurotrope BioScience’s PKC activator research (such as bryostatin), remain in full force and effect, in accordance with the conditions thereof. For the year ended December 31, 2015, Neurotrope BioScience incurred $ 2,052,595 20,000 On November 12, 2015, Neurotrope BioScience and BRNI entered into a new statement of Work Agreement (the “November 2015 SOW Agreement”) pursuant to the TLSA. The November 2015 SOW Agreement is effective as of November 1, 2015 and continues until December 31, 2016. Pursuant to the November 2015 SOW Agreement, Neurotrope BioScience agreed to pay BRNI one million one hundred sixty-six thousand six hundred sixty-six dollars ($ 1,166,666 83,333 500,000 On July 28, 2016, BRNI filed a petition for Chapter 11 Reorganization in the United States Bankruptcy Court for the District of West Virginia. As part of the bankruptcy filing, BRNI has asked the Bankruptcy Court to reject certain executory contracts including employment agreements with a number of its researchers and other personnel, including, without limitation, Dr. Daniel Alkon, who is our Chief Scientific Officer and also, as the scientific director of BRNI, has led a team of BRNI scientists who are involved on behalf of BRNI in support of the Neurotrope-BRNI License Agreement. BRNI has not requested that the Neurotrope-BRNI License Agreement itself be rejected. We do not believe that BRNI, as a matter of law, has a right to terminate the Neurotrope-BRNI License Agreement as a result of the bankruptcy filing and have been advised by BRNI’s representatives that there will be no action regarding the Neurotrope-BRNI License and that BRNI intends to meet all of its obligations in support of the Company’s work.

Income Taxes_

Income Taxes:	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7 – Income Taxes The Company incurred a net operating loss for income tax purposes of $ 26,725,315 9.3 373,000

Common Stock_

Common Stock:	6 Months Ended
	Jun. 30, 2016
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 – Common Stock: During the six months ended June 30, 2016, three holders of 4,300 0.0001 430,000 27,364 0.01 27,364 On April 12, 2016, the stockholders of the Company approved to increase the number of authorized shares of our Common Stock to 400,000,000

Stock Options_

Stock Options:	6 Months Ended
	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 9 – Stock Options The Board of Directors adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 7,000,000 On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 3,000,000 10,000,000 Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 8,582,952 $ 1.32 7.5 $ 0 Options granted 550,000 $ 0.60 Less options forfeited (280,418) $ 0.66 Less options expired/cancelled (20,000) $ 1.76 Less options exercised - $ 0.00 Options outstanding at June 30, 2016 8,832,534 $ 1.30 7.8 $ 0 Options exercisable at June 30, 2016 6,181,229 $ 1.39 7.3 $ 0 Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.01 - $ 0.71 1,078,082 9.11 $ 0.61 665,582 $ 0.61 $ 0.80 - $ 1.00 3,062,048 7.93 $ 0.93 1,478,024 $ 0.96 $ 1.11 - $ 1.55 1,120,000 7.74 $ 1.32 842,438 $ 1.25 $ 1.64 - $ 2.22 3,572,404 7.30 $ 1.82 3,195,185 $ 1.79 8,832,534 7.80 $ 1.30 6,181,229 $ 1.39 As of June 30, 2016, there were approximately $ 1.6 2.38 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options issued for the six months ended June 30, 2016 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 89.34 1.75 0.35 The total stock option-based compensation recorded as operating expense was $ 414,687 245,015 209,641 183,193

Common and Preferred Stock Rese

Common and Preferred Stock Reserved for Future Issuances:	6 Months Ended
	Jun. 30, 2016
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Common And Preferred Stock Reserved For Future Issuances [Text Block]	Note 10 – Common and Preferred Stock Reserved for Future Issuances Common Common stock warrants outstanding 134,800,876 Common stock for potential anti-dilution of warrants 66,712,722 Common stock options outstanding 8,832,534 Conversion of Series B Stock 25,804,940 Common stock for potential anti-dilution of Series B Stock 12,902,470 Total 249,053,542 On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 1,325,000 Resulting from the Private Placement, the Company is required to reserve shares of its common stock to accommodate up to an additional 50

Subsequent Events_

Subsequent Events:	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 11 – Subsequent Events From July 1, 2016 through August 12, 2016, holders of the Company’s Series B Stock converted a total of 1,000 100,000 On July 27, 2016, we received approval of the institutional review board (“IRB”) for our amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration (the “FDA”) relating to the Phase 2b clinical trial of our lead drug candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease, which amended protocol eliminates the second, exploratory, study period following the first 12 weeks of treatment. The primary objective is the assessment of safety and tolerability of bryostatin to occur at 13 weeks and that has not been changed with this amendment. The secondary objective is to assess efficacy, also at week 13. Such amendment, to cut the exploratory part of the study, was made for business reasons in order to provide earlier completion of the study and for the planning of future studies. The changes to the study design were not due to any safety concerns. In the study, two doses of bryostatin, 20µg or 40µg, will be compared to placebo. Study subjects receive a total of 7 doses of the study drug over 12 weeks of treatment, followed by safety and efficacy assessments at week 13 and a final study visit at week 16. There will be no second randomization for additional treatment. Subjects who have already entered into the second study period will be discontinued and evaluated 30 days following last treatment for their final study visit. Pending the robustness of trial enrollment, we expect to report data late in the first quarter or the beginning of the second quarter of 2017. On August 4, 2016, the Company reached a settlement agreement (the “Settlement Agreement”) with Iroquois Master Fund Ltd. and certain of its affiliates (collectively, “Iroquois”) to settle a proposed consent solicitation pertaining to the reconstitution of the Company’s Board of Directors (the “Board”). Pursuant to the Settlement Agreement, in consideration for Iroquois agreeing to discontinue its proposed consent solicitation to reconstitute the Board: (i) Board members Paul Freiman and Jay Haft resigned from the Board of the Company, its subsidiaries and all committees thereof, effective immediately; (ii) the Company’s Chief Executive Officer, Charles Ramat, entered into a Separation Agreement with the Company pursuant to which he shall resign, without cause, from the Board and all other positions that he holds with the Company, including Chief Executive Officer and President, on October 3, 2016 (unless the Board determines an earlier date) (the “Termination Date”) with Mr. Ramat remaining as a consultant to the Company until February 28, 2018; (iii) the Board appointed each of Mr. Joshua Silverman and Dr. Kenneth J. Gorelick to the Board, each to serve in accordance with the Company’s By-laws until his respective successor is duly elected and qualified or until his earlier resignation or removal; and (iv) the Company entered into a consulting agreement with SM Capital Management, LLC, a limited liability company owned and controlled by Mr. Joshua Silverman. Pursuant to the Ramat Separation Agreement, Mr. Ramat will continue to receive his current salary and benefits through the Termination Date except that his salary shall be reduced by $ 10,000 23,333 200,000 50,000 700,055 In connection with the resignations of each of Mr. Freiman and Mr. Haft from the Board, the Company entered into Director Separation Agreements, dated August 4, 2016, with each of Mr. Freiman and Mr. Haft (the “Director Separation Agreements”). Pursuant to such Director Separation Agreements, each of Mr. Freiman and Mr. Haft’s (i) outstanding unvested stock options, totaling 599,596 In addition, on August 4, 2016, the Company entered into a consulting agreement with SM Capital Management, LLC (“SMCM”), a limited liability company owned and controlled by Mr. Joshua Silverman (the “Consulting Agreement”). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM’s annual consulting fee is $ 120,000 10,000 On August 12, 2016, the Company’s Board of Directors increased the size of the Board of Directors from six to seven and appointed Ms. Shana Phares, President and Chief Executive of BRNI, to the Company’s Board of Directors. Ms. Phares replaces Mr. William Singer as a designee to the Board of Directors pursuant to the agreement between Neurotrope and Neuroscience Research Ventures, Inc. (NRV) dated November 12, 2015. Mr. Singer will remain as a member of the Board but no longer as an NRV designee.

Summary of Significant Accoun18

Summary of Significant Accounting Policies: (Policies)	6 Months Ended
	Jun. 30, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications: Certain reclassifications have been made to the 2015 financial statements to conform to the consolidated 2016 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At June 30, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment: June 30, December 31, Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (11,046) (7,595) Property and equipment, net $ 58,670 $ 59,175 Depreciation expense for the six months ended June 30, 2016 and 2015 was $ 3,451 3,049
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from BRNI that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at June 30, 2016 and December 31, 2015.
Income Tax, Policy [Policy Text Block]	Income Taxes: Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through June 30, 2016.
Income Tax Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties: The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation: The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of Common Stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements: In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to put most leases on their balance sheets by recognizing a lessee’s rights and obligations, while expenses will continue to be recognized in a similar manner to today’s legacy lease accounting guidance. This ASU could also significantly affect the financial ratios used for external reporting and other purposes, such as debt covenant compliance. This ASU will be effective for January 1, 2019, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation (Topic 718), which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. We are currently in the process of assessing the impact of this ASU on our consolidated financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies: (Tables)	6 Months Ended
	Jun. 30, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following: June 30, December 31, Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (11,046) (7,595) Property and equipment, net $ 58,670 $ 59,175

Stock Options_ (Tables)

Stock Options: (Tables)	6 Months Ended
	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity under the stock option plans for the six months ended June 30, 2016: Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 8,582,952 $ 1.32 7.5 $ 0 Options granted 550,000 $ 0.60 Less options forfeited (280,418) $ 0.66 Less options expired/cancelled (20,000) $ 1.76 Less options exercised - $ 0.00 Options outstanding at June 30, 2016 8,832,534 $ 1.30 7.8 $ 0 Options exercisable at June 30, 2016 6,181,229 $ 1.39 7.3 $ 0
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following is a summary of stock options outstanding under the plans as of June 30, 2016: Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.01 - $ 0.71 1,078,082 9.11 $ 0.61 665,582 $ 0.61 $ 0.80 - $ 1.00 3,062,048 7.93 $ 0.93 1,478,024 $ 0.96 $ 1.11 - $ 1.55 1,120,000 7.74 $ 1.32 842,438 $ 1.25 $ 1.64 - $ 2.22 3,572,404 7.30 $ 1.82 3,195,185 $ 1.79 8,832,534 7.80 $ 1.30 6,181,229 $ 1.39

Common and Preferred Stock Re21

Common and Preferred Stock Reserved for Future Issuances: (Tables)	6 Months Ended
	Jun. 30, 2016
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Common stock reserved for future issuances consisted of the following at June 30, 2016: Common Common stock warrants outstanding 134,800,876 Common stock for potential anti-dilution of warrants 66,712,722 Common stock options outstanding 8,832,534 Conversion of Series B Stock 25,804,940 Common stock for potential anti-dilution of Series B Stock 12,902,470 Total 249,053,542

Organization and Nature of Pl22

Organization and Nature of Planned Business: (Details Textual) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001

Summary of Significant Accoun23

Summary of Significant Accounting Policies: (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 69,716	$ 66,770
Accumulated depreciation	(11,046)	(7,595)
Property and equipment, net	$ 58,670	$ 59,175

Summary of Significant Accoun24

Summary of Significant Accounting Policies: (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Depreciation, Depletion and Amortization	$ 3,451	$ 3,049

Contractual Commitments_ (Detai

Contractual Commitments: (Details Textual)	Sep. 04, 2014USD ($)ft²	Jun. 30, 2016USD ($)
Contractual Commitments And Contingencies [Line Items]
Accrued Rent	$ 88,000
Area of Land | ft²	4,000
Description of Lessor Leasing Arrangements, Operating Leases	The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options.
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year		$ 136,100
Employment Agreements [Member]
Contractual Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year		380,000
Contractual Obligation, Due in Second Year		$ 350,000

Collaborative Agreements_ (Deta

Collaborative Agreements: (Details Textual) - USD ($)	Nov. 11, 2015	Oct. 09, 2015	May 15, 2014	Nov. 19, 2014	Jun. 30, 2016	Dec. 31, 2015
Collaborative Agreements [Line Items]
Estimated Budget For Services		$ 11,600,000
Payments for Advance to Affiliate	$ 1,875,861	$ 200,000
Service Fees	928,000
Pass Through Expenses	268,000
Investigator And Institute fees	680,000
Research and Development Expense [Member]
Collaborative Agreements [Line Items]
Percentage of Expenses of Total Amount Due					75.00%
January 2016 through September 2017 [Member]
Collaborative Agreements [Line Items]
Estimated Budget For Services	$ 9,500,000
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees			$ 715,159		$ 150,000
Reduction Of Commitment Fees				$ 657,238
Payments for Fees					837,112
Accounts Payable					0	$ 377,225
Worldwide Clinical Trials [Member]
Collaborative Agreements [Line Items]
Prepaid Expense					533,000
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
Annual License Maintenance Fee					10,000
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee					$ 29,400

Related Party Transactions an27

Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 12, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Sep. 30, 2016
Related Party Transaction [Line Items]
Technology Services Costs						$ 2,052,595
Research and Development Expense, Total		$ 925,942	$ 586,821	$ 1,818,679	$ 1,079,478
Due to Related Parties, Current		351,344		$ 351,344		$ 389,058
BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 1,166,666
Service Fees Third Party	$ 83,333
Blanchette Rockefeller Neurosciences Institute [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Research and Development Arrangement with Federal Government, Description and Terms				5 years
Post PA Fee Proceeds Percent	2.50%
Other Liabilities		$ 348,011		$ 348,011
BRNI [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Purchases from Related Party				500,000
Scenario, Forecast [Member] | BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Due to Related Parties							$ 20,000
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total				$ 1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage				5.00%
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 25,000,000
President [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		18.20%		18.20%

Income Taxes_ (Details Textual)

Income Taxes: (Details Textual)	44 Months Ended
	Jun. 30, 2016USD ($)
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$ 26,725,315
Deferred Tax Assets, Gross, Current	9,300,000
Deferred Tax Assets, Net	$ 373,000

Common Stock_ (Details Textual)

Common Stock: (Details Textual) - $ / shares	6 Months Ended
	Jun. 30, 2016	Apr. 12, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Common Stock, Shares Authorized	400,000,000	400,000,000	400,000,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted	4,300
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001
Neurotrope Inc. [Member] | Common Stock [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	430,000
Warrants Exercisable	27,364
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	27,364
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01

Stock Options_ (Details)

Stock Options: (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Options outstanding	8,582,952
Number of Shares, Options granted	550,000
Number of Shares, Less options forfeited	(280,418)
Number of Shares, Less options expired	(20,000)
Number of Shares, Less options exercised	0
Number of Shares, Options outstanding	8,832,534	8,582,952
Number of Shares, Options exercisable	6,181,229
Weighted-Average Exercise Price, Options outstanding	$ 1.32
Weighted-Average Exercise Price, Options granted	0.6
Weighted-Average Exercise Price, Less options forfeited	0.66
Weighted-Average Exercise Price, Less options expired	1.76
Weighted-Average Exercise Price, Less options exercised	0
Weighted-Average Exercise Price, Options outstanding	1.3	$ 1.32
Weighted-Average Exercise Price, Options exercisable	$ 1.39
Weighted-Average Remaining Contractual Term, Options outstanding (in years)	7 years 9 months 18 days	7 years 6 months
Weighted-Average Remaining Contractual Term, Options exercisable (in years)	7 years 3 months 18 days
Aggregate Intrinsic Value, Options outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Options exercisable	$ 0

Stock Options_ (Details 1)

Stock Options: (Details 1) - $ / shares	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding, Number of Shares	8,832,534	8,582,952
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 3 months 18 days
Weighted Avg. Exercise Price	$ 1.3	$ 1.32
Stock Options Exercisable, Number of Shares	6,181,229
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.39
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 0.71
Stock Options Outstanding, Number of Shares	1,078,082
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	9 years 1 month 10 days
Weighted Avg. Exercise Price	$ 0.61
Stock Options Exercisable, Number of Shares	665,582
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 0.61
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.80
Range of Exercise Prices, Upper Range Limit	$ 1
Stock Options Outstanding, Number of Shares	3,062,048
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 11 months 5 days
Weighted Avg. Exercise Price	$ 0.93
Stock Options Exercisable, Number of Shares	1,478,024
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 0.96
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.11
Range of Exercise Prices, Upper Range Limit	$ 1.55
Stock Options Outstanding, Number of Shares	1,120,000
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 8 months 26 days
Weighted Avg. Exercise Price	$ 1.32
Stock Options Exercisable, Number of Shares	842,438
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.25
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	1.64
Range of Exercise Prices, Upper Range Limit	$ 2.22
Stock Options Outstanding, Number of Shares	3,572,404
Stock Options Outstanding, Weighted Avg. Contractual Life (years)	7 years 3 months 18 days
Weighted Avg. Exercise Price	$ 1.82
Stock Options Exercisable, Number of Shares	3,195,185
Stock Options Exercisable, Weighted Avg. Exercise Price	$ 1.79

Stock Options_ (Details Textual

Stock Options: (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jul. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			89.34%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.75%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.35
Employee Benefits and Share-based Compensation	$ 209,641	$ 183,193	$ 414,687	$ 245,015
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 1,600,000		$ 1,600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 4 months 17 days
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	7,000,000		7,000,000
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					10,000,000
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					3,000,000

Common and Preferred Stock Re33

Common and Preferred Stock Reserved for Future Issuances: (Details)	Jun. 30, 2016shares
Class of Stock [Line Items]
Common Stock Reserved	249,053,542
Common stock warrants outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	134,800,876
Common stock options outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	8,832,534
Common stock for potential anti-dilution of warrants [Member]
Class of Stock [Line Items]
Common Stock Reserved	66,712,722
Conversion of Series B Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	25,804,940
Common stock for potential anti-dilution of Series B Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	12,902,470

Common and Preferred Stock Re34

Common and Preferred Stock Reserved for Future Issuances: (Details Textual) - shares	Feb. 09, 2015	Jun. 30, 2016	Jun. 30, 2015
Percentage of shares Reserved for Potential Dilution		50.00%
Conversion of Stock, Shares Issued		193,650	3,787,537
Warrant Holder [Member]
Conversion of Stock, Shares Issued	1,325,000
Series A Preferred Stock [Member] | Warrant Holder [Member]
Conversion of Stock, Shares Converted	1,325,000

Subsequent Events_ (Details Tex

Subsequent Events: (Details Textual) - Subsequent Event [Member] - USD ($)	Aug. 12, 2016	Aug. 31, 2016
SM Capital Management, LLC [Member]
Subsequent Event [Line Items]
Monthly Consulting Fee Installments payable		$ 10,000
Management Fee Payable		$ 120,000
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted	100,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	1,000
Management [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		599,596
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1		10 years
Supplemental Unemployment Benefits, Severance Benefits		$ 200,000
Management Fee Payable		$ 50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		700,055
Chief Executive Officer [Member] | Maximum [Member]
Subsequent Event [Line Items]
Officers' Compensation		$ 23,333
Chief Executive Officer [Member] | Minimum [Member]
Subsequent Event [Line Items]
Officers' Compensation		$ 10,000